» Articles » PMID: 12894246

The Emerging Role of Lysophosphatidic Acid in Cancer

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2003 Aug 2
PMID 12894246
Citations 483
Authors
Affiliations
Soon will be listed here.
Abstract

The bioactive phospholipid lysophosphatidic acid (LPA) stimulates cell proliferation, migration and survival by acting on its cognate G-protein-coupled receptors. Aberrant LPA production, receptor expression and signalling probably contribute to cancer initiation, progression and metastasis. The recent identification of ecto-enzymes that mediate the production and degradation of LPA, as well as the development of receptor-selective analogues, indicate mechanisms by which LPA production or action could be modulated for cancer therapy.

Citing Articles

A novel strategy for sorafenib-resistant hepatocellular carcinoma: autotaxin Inhibition by PF-8380.

Kwak B, Park J, Kim O, Lee D, Hong T, Lee S J Cancer Res Clin Oncol. 2025; 151(3):110.

PMID: 40082280 PMC: 11906571. DOI: 10.1007/s00432-025-06156-3.


Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention.

Contursi A, Tacconelli S, Di Berardino S, De Michele A, Patrignani P Front Pharmacol. 2025; 15:1520488.

PMID: 39764464 PMC: 11701038. DOI: 10.3389/fphar.2024.1520488.


Plasma metabolomics profiles and breast cancer risk.

Wu H, Lai Y, Liao Y, Deyssenroth M, Miller G, Santella R Breast Cancer Res. 2024; 26(1):141.

PMID: 39385226 PMC: 11463119. DOI: 10.1186/s13058-024-01896-5.


The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.

Inverso D, Tacconi C, Ranucci S, De Giovanni M Eur J Immunol. 2024; 54(12):e2350870.

PMID: 39263783 PMC: 11628915. DOI: 10.1002/eji.202350870.


Targeting the tumour vasculature: from vessel destruction to promotion.

Guelfi S, Hodivala-Dilke K, Bergers G Nat Rev Cancer. 2024; 24(10):655-675.

PMID: 39210063 DOI: 10.1038/s41568-024-00736-0.